• 1. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 5. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

Recent Advances in the Study of 1060805-54-0 and Methyl({4-(trifluoromethyl)pyridin-3-ylmethyl})amine in Chemical Biology and Pharmaceutical Research

The compound 1060805-54-0, along with its derivative methyl({4-(trifluoromethyl)pyridin-3-ylmethyl})amine, has garnered significant attention in recent chemical biology and pharmaceutical research. These molecules are part of a growing class of trifluoromethyl-substituted pyridine derivatives, which have demonstrated remarkable potential in drug discovery and development. Their unique structural features, including the presence of a trifluoromethyl group and a pyridine ring, contribute to enhanced metabolic stability, improved bioavailability, and selective target binding, making them valuable scaffolds for medicinal chemistry applications.

Recent studies have focused on the synthesis and optimization of 1060805-54-0 and its analogs, with particular emphasis on methyl({4-(trifluoromethyl)pyridin-3-ylmethyl})amine as a key intermediate. Advanced synthetic routes have been developed to improve yield and purity, including novel catalytic methods for introducing the trifluoromethyl group and efficient amine protection-deprotection strategies. These methodological advancements have enabled researchers to explore structure-activity relationships (SAR) more systematically, leading to the identification of promising lead compounds for various therapeutic targets.

In pharmacological investigations, methyl({4-(trifluoromethyl)pyridin-3-ylmethyl})amine has shown interesting activity as a building block for kinase inhibitors, particularly in the development of anti-cancer agents. The trifluoromethyl group's electron-withdrawing properties and the pyridine nitrogen's ability to form hydrogen bonds contribute to enhanced target binding affinity. Recent crystallographic studies have revealed that derivatives containing this moiety can effectively occupy the ATP-binding pocket of several oncogenic kinases, providing valuable insights for rational drug design.

Beyond oncology applications, research has expanded to explore the potential of these compounds in central nervous system (CNS) disorders. The lipophilic nature imparted by the trifluoromethyl group, combined with the appropriate molecular weight and polar surface area of methyl({4-(trifluoromethyl)pyridin-3-ylmethyl})amine derivatives, suggests promising blood-brain barrier permeability. Preliminary in vivo studies in animal models of neurodegenerative diseases have shown encouraging results, though further optimization is needed to improve selectivity and reduce off-target effects.

Recent computational studies have employed molecular docking and molecular dynamics simulations to predict the binding modes and stability of 1060805-54-0 derivatives with various biological targets. These in silico approaches, combined with experimental validation, have accelerated the identification of potential therapeutic applications. Notably, some analogs have shown activity against infectious disease targets, including viral proteases and bacterial enzymes, expanding the potential therapeutic scope of these compounds.

From a drug metabolism perspective, studies on methyl({4-(trifluoromethyl)pyridin-3-ylmethyl})amine have provided valuable data on the metabolic stability of trifluoromethyl-containing compounds. The presence of the trifluoromethyl group generally confers resistance to oxidative metabolism, while the pyridine ring can serve as a site for phase II conjugation reactions. Understanding these metabolic pathways is crucial for predicting drug-drug interactions and optimizing pharmacokinetic properties in future drug candidates.

In conclusion, the ongoing research on 1060805-54-0 and methyl({4-(trifluoromethyl)pyridin-3-ylmethyl})amine continues to reveal their versatility as privileged structures in medicinal chemistry. The combination of synthetic accessibility, favorable physicochemical properties, and diverse biological activities positions these compounds as valuable tools for drug discovery. Future research directions may include the development of more selective analogs, exploration of combination therapies, and investigation of novel therapeutic indications beyond those currently being explored.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)